Founded
Address
Third Rock Ventures LLC
29 Newbury Street
Boston, MA 02116
United States
Phone
Website
Recent investment activity
KANDO id: 1907
Company type
Venture capital firm focused on building healthcare companiesFunds managed
| Fund | Type | Vintage | Currency | Committed capital |
|---|---|---|---|---|
| Third Rock Ventures III LP | Venture | 2013 | USD | 516,000,000 |
| Third Rock Ventures II LP | Venture | 2010 | USD | 426,000,000 |
| Third Rock Ventures LP | Venture | 2007 | USD | 303,750,000 |
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 32| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Ablexis LLC | Biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery. | N/A | |||
|
|
Agios Pharmaceuticals Inc | N/A | ||||
|
|
Alcresta Inc | Developing and commercializing innovative enzyme-based nutritional products | N/A | |||
|
|
Allena Pharmaceuticals Inc | Developing and Commercializing Innovative Non-systemic Oral Protein Therapeutics | N/A | |||
|
|
Alnara Pharmaceuticals Inc | N/A | ||||
|
|
Bluebird Bio Inc | Developer of an innovative gene therapies for severe genetic disorders | Series D | |||
|
|
Bluebird Bio Inc | Developer of an innovative gene therapies for severe genetic disorders | Venture | |||
|
|
Bluebird Bio Inc | Developer of an innovative gene therapies for severe genetic disorders | Series B | |||
|
|
Blueprint Medicines | Develops cancer therapies, cancer genomics, and rational drugs that target the molecular aberrations that cause cancer. | N/A | |||
|
|
Edimer Pharmaceuticals Inc | Making an Impact for Future Generations Affected by the Rare and Painful Genetic Disorder XLHED | N/A | |||
|
|
Eleven Biotherapeutics Inc | A biotechnology company engineering and developing innovative protein-based therapeutics. | N/A | |||
|
|
Ember Therapeutics Inc | Revolutionizing the Treatment for Metabolic Disease | N/A | |||
|
|
Foundation Medicine Inc | N/A | ||||
|
|
Igenica Inc | A monoclonal-antibody discovery and development company | N/A | |||
|
|
Lotus Tissue Repair Inc | Developing Treatments for Rare Dermatologic Conditions | N/A | |||
|
|
NinePoint Medical Inc | A transformational medical device company, develops in vivo pathology medical devices. | N/A | |||
|
|
PanOptica Inc | A biopharmaceutical company, licenses and develops a portfolio of therapeutics for major ophthalmic diseases. | N/A | |||
|
|
Rhythm Pharmaceuticals Inc | N/A | ||||
|
|
SAGE Therapeutics | Develops and commercializes therapeutics and medicines for central nervous system (CNS) disorders. | N/A | |||
|
|
Seventh Sense Biosystems Inc | A medical device company optimizing the interface of diagnostic medicine and the healthcare consumer by simplifying blood sampling and testing. | N/A | |||
|
|
TOPICA Pharmaceuticals Inc | A privately held clinical research stage pharmaceutical company | N/A | |||
|
|
Warp Drive Bio LLC | Driving the Reemergence of Natural Products in the Era of Genomics | N/A | |||
|
|
Zafgen Inc | The world’s first biopharmaceutical company dedicated to developing novel obesity therapeutics. | N/A | |||
|
|
Afferent Pharmaceuticals Inc | N/A | ||||
|
Constellation Pharmaceuticals Inc | Rapidly Advancing Emerging Epigenetics Research to Develop Novel Oncology Therapeutics | Series B Follow-on investment |